Chris McConville is a highly motivated and enthusiastic Professor of Biomedical Innovation with an internationally recognised research portfolio in pharmaceutics, drug delivery, formulation and pharmaceutical engineering. He has an extensive publication record in leading international journals in his field and has raised significant levels (>£20 million) of funding for his research. Chris leads an active research group in the field of drug formulation and delivery, with a focus on implantable devices and nanotechnology for the improvement of cancer treatment. His recent work has focused on the development of an implantable device for the local delivery of chemotherapy to the brain (ChemoSeed®) as well as a device for the delayed and localised delivery of chemotherapy to the pancreatic cancer margin. Through his research Chris has established a number of impactful collaborative links with academic, clinical and industrial partners.In addition, Chris is founder and Chief Scientific Officer at CRISM Therapeutics Ltd a publicly listed company on AIM set up for the commercialisation of ChemoSeed®, an implantable drug delivery device designed to be implanted at the surgical margin of a brain tumour, improving the delivery of chemotherapy to the tumour margin while reducing systemic toxicities. This approach will improve the efficacy of brain tumour treatment, while reducing the side effect burden on patients. ChemoSeed for other cancers (bladder, prostate, liver and breast) are currently development as well as ChemoSeeds capable of the delivery of multiple drugs and personalised treatments.Chris also provides consultancy to the pharmaceutical industry on drug formulation and delivery, particularly in the areas of Chemistry Manufacturing and Control (CMC), sustained drug delivery, implantable devices, nanotechnology, hot melt extrusion, injection moulding and 3D printing.